Tellus BioVentures

News

Interius BioTherapeutics Raises $76M Series A Financing to Advance Breakthrough Cell and Gene Therapy Platform

05/18/21 Interius BioTherapeutics, a preclinical stage gene therapy company developing a paradigm-shifting platform for in vivo cell-specific gene delivery, today announced that it has raised $76 million in an oversubscribed Series A financing.

Read More >

Recent Stories

Two M&A deals and $9B later, Lonnie Moulder is ramping up his latest biotech startup. And this one comes with global vision built in.

Mar 23, 2021

MiRagen Therapeutics Announces Company Name Change to Viridian Therapeutics and New Executive Appointments

Jan 19, 2021

MiRagen Therapeutics, Inc. Announces Acquisition of Viridian Therapeutics, Inc.

Oct 28, 2020

FDA Grants Fast Track Status to Aegle Therapeutics’ AGLE-102 for the Treatment of Dystrophic Epidermolysis Bullosa

Oct 01, 2020

Aegle Therapeutics Completes $6.5M Series A Financing

Sep 29, 2020

Latest Penn biotech spinout taking on cancer raises $1.6M from investors

Mar 31, 2020

Zai Lab Appoints Lonnie Moulder to Board of Directors

Jan 14, 2020

Helsinn appoints Eric Cornut and Lonnie Moulder to the Board of Directors

Jan 13, 2020

Aegle Therapeutics Announces $4M Financing to Fund Groundbreaking Stem Cell Exosome Clinical Trial to Treat Orphan Disease Dystrophic Epidermolysis Bullosa

Jan 07, 2020

All News